Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 10,550,000 shares, a decline of 6.1% from the November 15th total of 11,230,000 shares. Based on an average trading volume of 788,200 shares, the short-interest ratio is currently 13.4 days. Approximately 19.5% of the company’s stock are short sold.

Analysts Set New Price Targets

GPCR has been the subject of several recent research reports. HC Wainwright assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, December 4th. They issued a “buy” rating and a $80.00 price objective for the company. Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $85.67.

Structure Therapeutics Trading Up 1.5 %

GPCR stock opened at $31.48 on Wednesday. The firm has a 50 day simple moving average of $35.95 and a 200-day simple moving average of $39.17. The company has a market capitalization of $1.80 billion, a P/E ratio of -42.54 and a beta of -3.41. Structure Therapeutics has a twelve month low of $26.61 and a twelve month high of $62.74.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its stake in shares of Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares in the last quarter. FMR LLC increased its holdings in Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after buying an additional 383,635 shares during the last quarter. Janus Henderson Group PLC raised its stake in Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares in the last quarter. Driehaus Capital Management LLC lifted its holdings in Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after buying an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in shares of Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock worth $94,531,000 after acquiring an additional 150,000 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.